_files/lancet-lancet.jpg)
Development of a rational scale to assess the harm of drugs of potential misuse
_files/article_notepad.gif)
_files/icon_email.png){kind=icon}
_files/526.png)
_files/expand.gif)
Article InfoTo view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.
Figure 1
Mean harm scores for 20 substances
Classification under the Misuse of Drugs Act, where appropriate, is shown by the colour of each bar.
Figure 2
Correlation between mean scores from the independent experts and the specialist addiction psychiatrists
1=heroin. 2=cocaine. 3=alcohol. 4=barbiturates. 5=amphetamine. 6=methadone. 7=benzodiazepines. 8=solvents. 9=buprenorphine. 10=tobacco. 11=ecstasy. 12=cannabis. 13=LSD. 14=steroids.
Summary
Drug misuse and abuse are major health problems. Harmful drugs are regulated according to classification systems that purport to relate to the harms and risks of each drug. However, the methodology and processes underlying classification systems are generally neither specified nor transparent, which reduces confidence in their accuracy and undermines health education messages. We developed and explored the feasibility of the use of a nine-category matrix of harm, with an expert delphic procedure, to assess the harms of a range of illicit drugs in an evidence-based fashion. We also included five legal drugs of misuse (alcohol, khat, solvents, alkyl nitrites, and tobacco) and one that has since been classified (ketamine) for reference. The process proved practicable, and yielded roughly similar scores and rankings of drug harm when used by two separate groups of experts. The ranking of drugs produced by our assessment of harm differed from those used by current regulatory systems. Our methodology offers a systematic framework and process that could be used by national and international regulatory bodies to assess the harm of current and future drugs of abuse.
This article is available free of charge.
Already registered? Please login.
Register
Create a new accountThe Lancet Choice
_files/TL_choice.gif)
The Lancet Choice is a new payment option that gives you the freedom and flexibility to access any 5 premium articles of your choice from across The Lancet family of journals - all for a one-off payment of $49.00 USD.
Simply purchase your Lancet Choice pass from the Summary or Full Text page of an article you wish to access. This will count as the first of 5 article credits, or ‘Allowances’, and you can use your 4 remaining Allowances to access other articles from any of The Lancet journals.
_files/pdf_icon.png "Download PDF"){kind=icon}